Clinical trial
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma…
NCT00238303 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00238303 |
|---|---|
| Title | Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme |
| Official title | Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Recurrent Glioblastoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor |
| Intervention type | Drug, Procedure |
| Interventions | vorinostat, conventional surgery |
| Enrollment | 103 |
| Start date | Sep 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Mar 1, 2010 |
| First posted | Oct 13, 2005 |
| Last update posted | May 23, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: